Amgen reports Q1 adjusted EPS $5.15, consensus $4.77

Reports Q1 revenue $8.6B, consensus $8.57B. “Our first quarter results demonstrate the strength of our business, with 16 brands achieving double-digit growth, enabling us to grow through expected patent expirations and increased competition. With a new wave of molecules progressing in Phase 3 clinical development, we’re confident in our ability to deliver attractive long-term growth,” said Robert Bradway, chairman and chief executive officer.